Format

Send to

Choose Destination
Biochimie. 2018 Feb;145:125-130. doi: 10.1016/j.biochi.2017.09.006. Epub 2017 Sep 11.

Selection of PD1/PD-L1 X-Aptamers.

Author information

1
Institute of Molecular Medicine, University of Texas Health Science Center at Houston, 1825 Pressler Street, Houston, TX, 77030, USA.
2
AM Biotechnologies, LLC, 12521 Gulf Freeway, Houston, TX, 77034, USA.
3
Institute of Molecular Medicine, University of Texas Health Science Center at Houston, 1825 Pressler Street, Houston, TX, 77030, USA; Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, 1825 Pressler Street, Houston, TX, 77030, USA.
4
AM Biotechnologies, LLC, 12521 Gulf Freeway, Houston, TX, 77034, USA. Electronic address: xianbin.yang@am-biotech.com.

Abstract

Specific, chemically modified aptamers (X-Aptamers) were identified against two immune checkpoint proteins, recombinant Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1). Selections were performed using a bead-based X-Aptamer (XA) library containing several different amino acid functional groups attached to dU at the 5-position. The binding affinities and specificities of the selected XA-PD1 and XA-PDL1 were validated by hPD-1 and hPD-L1 expression cells, as well as by binding to human pancreatic ductal adenocarcinoma tissue. The selected PD1 and PDL1 XAs can mimic antibody functions in in vitro assays.

PMID:
28912094
PMCID:
PMC5794648
DOI:
10.1016/j.biochi.2017.09.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center